A classic hallmark of wet age-related macular degeneration (AMD) is choroidal neovascularization (CNV). In order to help global customers better understand and develop novel treatments for wet ADM, Ace Therapeutics has created the most comprehensive and reliable choroidal neovascularization model platform. In addition, you will benefit from our advanced non-invasive fluorescein angiography imaging system, which ensures the model's reliability to a significant extent.
Choroidal neovascularization (CNV) is a significant feature of ocular diseases such as wet age-related macular degeneration (AMD) and pathological myopia. However, CNV pathogenic mechanisms are complex and unknown. To better understand this disease process and explore therapeutics to treat it, it is necessary to create experimental animal models that are stable, efficient, and reproducible. These models must exhibit pathological features similar to those observed in human CNV lesions.
Fig. 1. Laser-induced CNV model. (Liu CH, et al., 2017)
Wet age-related macular degeneration (AMD) is the leading cause of blindness in older adults. As an industry-leading company in ocular disease solutions, Ace Therapeutics scientists have developed a rodent choroidal neovascularization model for wet age-related macular degeneration research. Importantly, we can work with you at any stage of project development to expedite project timelines in all application areas.
The laser CNV model has been an ideal animal model for developing treatments for wet age-related macular degeneration (wet AMD). Ace Therapeutics researchers induce a successful CNV model by creating laser burns around the optic disc (OD) of C57BL/6 mice. These animal models are highly relevant to CNVs that occasionally occur in human eyes after accidental laser burns.
Although the laser CNV model results in CNV in approximately 80% of lesions, in fact, subretinal injection model is more valid and reliable in evaluating anti-VEGF gene therapy strategies. Ace Therapeutics researchers create a rodent model of choroidal neovascularization (CNV) by subretinal injection of polyethylene glycol (PEG) in C57BL/6 mice.
Proudly, Ace Therapeutics' study design and model development services are flexible. Our researchers can select the appropriate species (rat or mouse) based on the properties of the client compound (activity, mode of delivery, stage of development) and the intended clinical application. To verify the high reliability of the model, Ace Therapeutics researchers develop a series of non-invasive fluorescein angiography imaging systems for visualization and quantitative assessment of leakage and lesion size, including:
Ace Therapeutics is committed to being your trusted partner in eye disease research. We provide unparalleled choroidal neovascularization model development services to our global clients. If you are interested in our services or need more detailed information, please feel free to contact us. Our experienced scientists are ready to help you!
References